

**Ethos delivered 4% better EBITDA led by strategic curtailing of marketing spends. Despite operating challenges across the entire retail spectrum, Ethos has outperformed with strong 19% revenue growth (12.3% SSG) in Q1 vs single-digit growth for most retailers. With the return of normalcy, Ethos' outperformance is likely going to further accelerate with 28% growth in Jul-24, along with better gross margin. Ethos added 4 stores in FY25TD with faster expansion in coming quarters; it has retained its annual outlook to add ~20 stores. The company expects continued momentum over the medium term, supported by TAM expansion/own brand, ramp up of the Lifestyle vertical, and faster growth in pre-owned watches. Ethos also has tangible margin/WC tailwinds via gradual reduction in customs duty, higher exclusive mix, lower discounts, and better credit terms from brands. Our estimates remain largely unchanged, but we are increasing TP multiple by 5% to 37x Sep-26E EBITDA. We retain BUY with revised Sep-25E TP of Rs3,700/share (vs Jun-25E earlier).**

#### Ethos: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	7,885	9,990	12,489	16,033	20,297
EBITDA	1,144	1,498	2,020	2,741	3,615
Adj. PAT	603	814	1,062	1,379	1,847
Adj. EPS (Rs)	25.8	33.2	43.4	56.3	75.5
EBITDA margin (%)	14.5	15.0	16.2	17.1	17.8
EBITDA growth (%)	71.0	30.9	34.8	35.7	31.9
Adj. EPS growth (%)	110.7	28.7	30.4	29.9	34.0
RoE (%)	14.0	10.7	11.3	13.0	15.1
RoIC (%)	18.7	16.4	18.1	20.2	22.2
P/E (x)	121.6	94.4	72.4	55.7	41.6
EV/EBITDA (x)	62.1	49.0	36.4	26.9	20.4
P/B (x)	11.6	8.7	7.8	6.8	5.9
FCFF yield (%)	(0.8)	(0.1)	0.4	0.5	1.2

Source: Company, Emkay Research

**Strong performance despite operating challenges; Q2TD sees robust pickup:** Q1 revenue grew by a healthy 19% to Rs2.7bn led by 12.3% SSG, with the balance growth coming from network expansion. The ASP grew ~25% in Q1 implying 5-6% de-growth in overall volumes which is mainly due to reduced focus on <Rs50k watch segment and elections-led restriction on carrying cash; both together impacted volumes for <Rs250K. However, volume growth for non-cash watch segment (>Rs250k) was healthy at 9.5%. Exclusive brands mix remained flat at ~30% in Q1. Exclusive brand count reached ~55 with 2 new added in Q1 – *ID Geneve* and *Singer Reimagined*. The CPO business clocked ~Rs0.2bn for Q1, registering a strong 31% growth. Ethos is seeing good traction in new Lifestyle business with Rimova witnessing ~Rs20mn monthly run-rate. Gross margin declined by 80bps to 29.6% in Q1, led by higher discounts/promotions amid the challenging operating environment. Despite dip in GM, the lower employee costs (~60bps) and curtailed marketing spends led to a ~110bps higher EBITDA margin at 15.8%. Pre-IndAS EBITDA improved by 60bps to 11.1% in Q1 vs 10.5% last year. The delay in mall constructions led to slower store add of 3 in Q1 (66 total stores currently), but the outlook remains intact with 20-25 additions in FY25.

**Strong commentary keeps us optimistic:** i) Q1 realizations were up ~25% with <Rs250k watch segment impacted due to implementation of model code of conduct amid general elections, strong heatwaves, inclement weather-led logistics issue in Switzerland, and implementation of a new ERP system (3 days impact). However, Ethos indicated strong recovery in July with ~28% growth and better gross margin. ii) Store additions are expected to accelerate between Oct-24 and Mar-25 as the delay is largely due to real estate related regulatory challenges. iii) Ethos remained confident of partnering with ultra-luxury watch brands which are yet to enter India and will aid in its TAM expansion. In addition, the initial success in Rimova is strengthening Ethos' confidence for more tie-ups in the Lifestyle vertical. It is already in initial discussion stage with such brands and expects to sign a few of them within 12-18 months. i) Ethos has a clear roadmap for 8-10 *Rimova* stores and has also finalized the 1<sup>st</sup> *Messika* store in New Delhi. v) Gross margin dip in Q1 was largely due to higher discount offers/price matching; however, the discounting has likely reduced with Ethos indicating a strong gross margin performance in Jul-24. vi) *Favre Leuba*'s first collection will be launched at Geneva Watch Days (Aug-24 end). vii) Ethos expects to retain the entire margin benefit from duty reduction for ~90% of exclusive brands, and share margin benefits with the remaining 10% of exclusive brands. Ethos is also negotiating with non-exclusive brands to share the waiver benefit. viii) While the pre-owned business has the potential to grow even faster vs current growth trends of ~30%, the growth is being restricted due to shortage of skilled watchmakers. With the Delhi center running at full capacity, Ethos is opening a second service center in Bengaluru to cater to the same. It has also tied up with a Swiss training organization to improve availability and training of watchmakers.


Target Price – 12M	Sep-25
Change in TP (%)	15.6
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	17.9
CMP (14-Aug-24) (Rs)	3,139.3

Stock Data	Ticker
52-week High (Rs)	3,380
52-week Low (Rs)	1,542
Shares outstanding (mn)	24.5
Market-cap (Rs bn)	77
Market-cap (USD mn)	915
Net-debt, FY25E (Rs mn)	-3,309
ADTV-3M (mn shares)	-
ADTV-3M (Rs mn)	133.5
ADTV-3M (USD mn)	1.6
Free float (%)	36.0
Nifty-50	24,144
INR/USD	83.9
<b>Shareholding, Jun-24</b>	
Promoters (%)	54.7
FPIs/MFs (%)	11.2/14.1

#### Price Performance

(%)	1M	3M	12M
Absolute	6.3	30.2	91.8
Rel. to Nifty	7.9	19.8	54.4

#### 1-Year share price trend (Rs)



#### Devanshu Bansal


devanshu.bansal@emkayglobal.com  
+91 22 6612 1385

#### Vishal Panjwani

vishal.panjwani@emkayglobal.com  
+91 22 6624 2431


## Story in Charts

**Exhibit 1: Topline grew 19%, led by ~12% SSG with the remaining helped by growth in the average store count**




Source: Company, Emkay Research

**Exhibit 2: Gross margin decline was due to higher promotions; still EBITDA margin was up on low employee cost/curtailed marketing**



Source: Company, Emkay Research

**Exhibit 3: Cost-control measures helped keep other expenses under control in Q1**




Source: Company, Emkay Research

**Exhibit 4: Ethos added 3 stores in Q1; guidance to add 20-25 store was intact with pace expected to pickup from Q2**




Source: Company, Emkay Research

**Exhibit 5: Share of luxury and high-luxury watch sales increased to 73%, helped by operating challenges in <250K watch segment**




Source: Emkay Research (Ballpark numbers based on analyst's calculation)

**Exhibit 6: ASP increased ~25%, led by both, mix improvements toward high-end watches and price hikes**



Source: Emkay Research (Ballpark numbers based on analyst's calculation)

**Exhibit 7: The CHF-INR CY24TD trend has been stable vs the sharp 12% depreciation in CY23; gross margin is likely to remain stable with brand MRP now largely in line with the current CHF-INR trend**



Source: Company, Emkay Research

This report is intended for team emkay@whitemarquesolutions.com use and downloaded at 08/21/2024 11:36 AM

Emkay Research is also available on [www.emkayglobal.com](http://www.emkayglobal.com) and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

**Exhibit 8: Swiss exports to India have seen strong growth of ~15% in CY24TD in CHF terms; Ethos has outperformed with ~20% growth in the comparable period**

Swiss watch exports to India (CHF mn)	CY18	CY19	CY20	CY21	CY22	CY23	CY23TD	CY24TD	YoY (%)
January	12.6	10.9	11.4	10.3	10.7	13.9	13.9	13.6	-2.2
February	14.5	14.2	12.0	12.4	12.6	15.7	15.7	20.7	31.8
March	12.1	14.5	3.4	14.3	13.7	18.4	18.4	20.1	9.2
<b>April</b>	<b>11.7</b>	<b>11.3</b>	<b>0.0</b>	<b>10.9</b>	<b>14.0</b>	<b>14.7</b>	<b>14.7</b>	<b>17.2</b>	<b>17.0</b>
<b>May</b>	<b>12.7</b>	<b>11.3</b>	<b>0.3</b>	<b>6.8</b>	<b>15.0</b>	<b>16.1</b>	<b>16.1</b>	<b>21.7</b>	<b>34.8</b>
<b>June</b>	<b>11.4</b>	<b>10.0</b>	<b>4.9</b>	<b>5.0</b>	<b>15.2</b>	<b>19.7</b>	<b>19.7</b>	<b>19.5</b>	<b>-1.0</b>
July	11.5	11.2	7.4	11.3	17.4	17.7			
August	11.1	10.3	7.9	12.9	14.2	17.5			
September	15.3	13.8	10.5	15.0	17.8	20.5			
October	13.4	12.4	12.4	21.6	23.0	22.3			
November	12.8	14.4	15.7	17.3	16.9	19.8			
December	13.6	11.7	12.9	19.0	17.3	22.8			
<b>Total</b>	<b>152.7</b>	<b>146.1</b>	<b>98.8</b>	<b>156.8</b>	<b>187.8</b>	<b>219.1</b>	<b>98.5</b>	<b>112.8</b>	<b>14.5</b>

Source: Federation of the Swiss Watch Industry, Emkay Research

**Exhibit 9: Actual vs Estimates (Q1FY25)**

(Rs mn)	Actual	Emkay estimate	Variation	Comments
Net Sales	2,732	2,761	-1.0%	Topline was in line with our estimates
EBITDA	433	416	4.1%	EBITDA margin was higher led by curtailed marketing spends
EBITDA margin	15.8%	15.1%	78	
PAT	228	230	-0.8%	PAT came in line with estimate due to higher depreciation

Source: Company, Emkay Research

## Exhibit 10: Summary of quarterly results

Y/E, Mar (Rs mn)	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	YoY (%)	QoQ (%)	FY23	FY24	Gr (%)
<b>Revenue</b>	<b>2,300</b>	<b>2,352</b>	<b>2,812</b>	<b>2,525</b>	<b>2,732</b>	<b>18.8</b>	<b>8.2</b>	<b>7,885</b>	<b>9,990</b>	<b>26.7</b>
<b>Expenditure</b>	<b>1,961</b>	<b>1,979</b>	<b>2,367</b>	<b>2,165</b>	<b>2,300</b>	<b>17.3</b>	<b>6.2</b>	<b>6,741</b>	<b>8,473</b>	<b>25.7</b>
Consumption of RM	1,602	1,618	1,975	1,789	1,923	20.1	7.5	5,444	6,984	28.3
As a % of sales	70%	69%	70%	71%	70%			69%	70%	
Employee Cost	174	173	163	194	190	9.4	-2.0	527	704	33.6
As a % of sales	8%	7%	6%	8%	7%			7%	7%	
Other expenditure	185	189	229	183	187	0.6	2.1	771	786	1.9
As a % of sales	9%	10%	10%	8%	8%			10%	8%	
<b>EBITDA</b>	<b>339</b>	<b>373</b>	<b>445</b>	<b>360</b>	<b>433</b>	<b>27.6</b>	<b>20.3</b>	<b>1,144</b>	<b>1,517</b>	<b>32.6</b>
Depreciation	107	127	125	127	143	33.5	12.5	346	487	40.6
<b>EBIT</b>	<b>232</b>	<b>246</b>	<b>320</b>	<b>233</b>	<b>290</b>	<b>24.9</b>	<b>24.5</b>	<b>798</b>	<b>1,030</b>	<b>29.2</b>
Other Income	47	43	62	84	64	36.5	-24.1	146	236	62.2
Interest	38	41	40	40	45	19.3	12.1	142	160	13.1
<b>PBT</b>	<b>241</b>	<b>247</b>	<b>342</b>	<b>276</b>	<b>308</b>	<b>28.0</b>	<b>11.5</b>	<b>802</b>	<b>1,106</b>	<b>38.0</b>
Total Tax	61	63	88	67	79	28.2	17.3	204	280	37.5
<b>APAT</b>	<b>179</b>	<b>184</b>	<b>254</b>	<b>209</b>	<b>230</b>	<b>27.9</b>	<b>9.7</b>	<b>598</b>	<b>826</b>	<b>38.2</b>
<b>Share of JV profit</b>	<b>-2</b>	<b>-2</b>	<b>-1</b>	<b>-1</b>	<b>2</b>			<b>-5</b>	<b>-7</b>	
<b>Reported PAT</b>	<b>182</b>	<b>186</b>	<b>255</b>	<b>210</b>	<b>228</b>	<b>25.6</b>	<b>8.4</b>	<b>603</b>	<b>833</b>	<b>38.1</b>
<b>Reported EPS (Rs)</b>	<b>7.8</b>	<b>8.0</b>	<b>10.9</b>	<b>9.0</b>	<b>9.8</b>	<b>25.6</b>	<b>8.4</b>	<b>28.5</b>	<b>35.7</b>	<b>25.0</b>
<b>(%)</b>	<b>Q1FY24</b>	<b>Q2FY24</b>	<b>Q3FY24</b>	<b>Q4FY24</b>	<b>Q1FY25</b>	<b>(bps)</b>	<b>(bps)</b>	<b>FY23</b>	<b>FY24</b>	<b>(bps)</b>
Gross Margin	30.4	31.2	29.8	29.2	29.6	-70	50	31.0	30.1	-90
EBITDAM	14.7	15.8	15.8	14.2	15.8	110	160	14.5	15.2	70
EBITM	10.1	10.4	11.4	9.2	10.6	50	140	10.1	10.3	20
PBTM	10.5	10.5	12.2	10.9	11.3	80	30	10.2	11.1	90
PATM	7.8	7.8	9.0	8.3	8.4	60	10	7.6	8.3	70
Effective Tax rate	25.5	25.6	25.8	24.3	25.5	0	130	25.4	25.3	-10.0

Source: Company, Emkay Research

## Exhibit 11: Peer Comparison

Companies	Price (Rs)	Mcap (Rs bn)	Reco	Target Price (Rs/sh)	EPS (Rs)			P/E (x)			EV/EBITDA (x)*		
					FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Titan Company	3,402	3,020	Buy	4,000	38.4	55.9	73.4	88.7	60.9	46.3	50.4	40.6	32.5
Page Industries	40,700	454	Reduce	37,300	593.0	713.7	845.7	68.6	57.0	48.1	44.7	37.7	32.1
Jubilant FoodWorks	637	421	Add	600	4.5	7.5	10.0	142.3	84.5	63.7	26.0	21.7	18.8
Devyani International	170	206	Reduce	175	0.9	1.4	2.2	195.2	123.0	78.7	22.5	18.2	14.9
ABFRL	311	316	Sell	260	-3.5	-0.8	0.1	NA	NA	NA	18.1	13.4	11.0
Westlife Foodworld	800	125	Reduce	875	2.0	8.1	11.6	402.2	99.1	69.0	34.7	23.8	19.6
Sapphire Foods	1,536	98	Add	1,700	9.3	20.4	32.1	166.0	75.3	47.8	18.0	13.6	10.7
Go Fashion	1,107	60	Buy	1,350	20.1	27.1	33.3	55.1	40.8	33.2	19.9	15.6	12.8
<b>Ethos</b>	<b>3,139</b>	<b>77</b>	<b>Buy</b>	<b>3,700</b>	<b>43.4</b>	<b>56.3</b>	<b>75.5</b>	<b>72.4</b>	<b>55.7</b>	<b>41.6</b>	<b>36.4</b>	<b>26.8</b>	<b>20.3</b>
Senco Gold	1,099	85	Buy	1,400	29.2	40.0	49.0	37.7	27.5	22.4	17.3	15.0	12.5
Varun Beverages	1,462	1,900	Add	1,650	19.2	25.3	32.0	76.3	57.8	45.7	42.2	34.9	29.4
Aditya Vision	4,518	58	Buy	5,800	96.2	132.7	180.6	47.0	34.0	25.0	25.6	19.5	15.0

Source: Company, Emkay Research; Note: \*Post-IndAS-116 EBITDA

Exhibit 12: Changes in estimates

(Rs mn)	FY25E			FY26E			FY27E		
	Old	New	% change	Old	New	Change (%)	Old	New	Change (%)
Revenue	12,248	12,489	2.0	15,988	16,033	0.3	20,246	20,297	0.3
EBITDA*	1,414	1,454	2.8	1,987	2,005	0.9	2,680	2,694	0.5
EBITDA margin (%)	11.5	11.6	10 bps	12.4	12.5	10 bps	13.2	13.3	0 bps
Net profit	1,040	1,062	2.1	1,365	1,379	1.0	1,836	1,847	0.6
EPS (Rs)	42.5	43.4	2.1	55.7	56.3	1.0	75.0	75.5	0.6

Source: Company, Emkay Research, Note: \*Pre-IndAS 116 EBITDA

Ethos: Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Revenue	7,885	9,990	12,489	16,033	20,297
Revenue growth (%)	36.6	26.7	25.0	28.4	26.6
EBITDA	1,144	1,498	2,020	2,741	3,615
EBITDA growth (%)	71.0	30.9	34.8	35.7	31.9
Depreciation & Amortization	346	487	632	832	1,040
EBIT	798	1,011	1,388	1,909	2,575
EBIT growth (%)	125.4	26.8	37.3	37.5	34.8
Other operating income	0	0	0	0	0
Other income	146	236	230	180	200
Financial expense	142	160	199	246	305
PBT	802	1,087	1,419	1,843	2,469
Extraordinary items	0	0	0	0	0
Taxes	204	280	358	464	622
Minority interest	0	0	0	0	0
Income from JV/Associates	5	7	0	0	0
Reported PAT	603	814	1,062	1,379	1,847
PAT growth (%)	157.8	35.0	30.4	29.9	34.0
Adjusted PAT	603	814	1,062	1,379	1,847
Diluted EPS (Rs)	25.8	33.2	43.4	56.3	75.5
Diluted EPS growth (%)	110.7	28.7	30.4	29.9	34.0
DPS (Rs)	0.0	0.0	0.0	0.0	0.0
Dividend payout (%)	0.0	0.0	0.0	0.0	0.0
EBITDA margin (%)	14.5	15.0	16.2	17.1	17.8
EBIT margin (%)	10.1	10.1	11.1	11.9	12.7
Effective tax rate (%)	25.4	25.8	25.2	25.2	25.2
NOPLAT (pre-IndAS)	595	751	1,038	1,428	1,926
Shares outstanding (mn)	23.3	24.5	24.5	24.5	24.5

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
PBT	802	1,087	1,419	1,843	2,469
Others (non-cash items)	346	487	632	832	1,040
Taxes paid	(204)	(280)	(358)	(464)	(622)
Change in NWC	(985)	(1,007)	(850)	(1,349)	(1,538)
Operating cash flow	(39)	237	812	928	1,454
Capital expenditure	(558)	(298)	(485)	(545)	(545)
Acquisition of business	(5)	(219)	(60)	(50)	0
Interest & dividend income	146	236	230	180	200
Investing cash flow	(547)	(281)	(315)	(415)	(345)
Equity raised/(repaid)	3,397	1,750	0	0	0
Debt raised/(repaid)	(514)	(13)	0	0	0
Payment of lease liabilities	(318)	(423)	(566)	(736)	(920)
Interest paid	(26)	(9)	(10)	(10)	(10)
Dividend paid (incl tax)	0	0	0	0	0
Others	(64)	(93)	0	0	0
Financing cash flow	2,474	1,212	(576)	(746)	(930)
Net chg in Cash	1,888	1,168	(79)	(234)	179
OCF	(39)	237	812	928	1,454
Adj. OCF (w/o NWC chg.)	945	1,244	1,662	2,277	2,992
FCFF	(597)	(61)	327	383	909
FCFE	(593)	15	358	317	804
OCF/EBITDA (%)	(3.4)	15.8	40.2	33.8	40.2
FCFE/PAT (%)	(98.4)	1.9	33.8	23.0	43.5
FCFF/NOPLAT (%)	(100.4)	(8.1)	31.5	26.8	47.2

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY23	FY24	FY25E	FY26E	FY27E
Share capital	233	245	245	245	245
Reserves & Surplus	6,081	8,595	9,656	11,035	12,882
Net worth	6,315	8,840	9,901	11,280	13,127
Minority interests	0	0	0	0	0
Deferred tax liability (net)	(86)	0	0	0	0
Total debt	80	67	67	67	67
Total liabilities & equity	6,309	8,907	9,968	11,347	13,194
Net tangible fixed assets	138	305	629	964	1,250
Net intangible assets	407	398	396	390	378
Net ROU assets	(93)	(129)	(221)	(336)	(480)
Capital WIP	40	0	0	0	0
Goodwill	0	0	0	0	0
Investments [JV/Associates]	21	240	300	350	350
Cash & equivalents	2,286	3,455	3,376	3,142	3,321
Current assets (ex-cash)	4,085	5,172	6,261	7,951	9,898
Current Liab. & Prov.	966	960	1,200	1,540	1,950
NWC (ex-cash)	3,119	4,212	5,062	6,411	7,949
Total assets	6,309	8,907	9,968	11,347	13,194
Net debt	(2,206)	(3,388)	(3,309)	(3,075)	(3,254)
Capital employed	6,309	8,907	9,968	11,347	13,194
Invested capital	3,962	5,212	6,293	7,855	9,523
BVPS (Rs)	270.5	361.1	404.5	460.8	536.2
Net Debt/Equity (x)	(0.3)	(0.4)	(0.3)	(0.3)	(0.2)
Net Debt/EBITDA (x)	(1.9)	(2.3)	(1.6)	(1.1)	(0.9)
Interest coverage (x)	0.2	0.1	0.1	0.1	0.1
RoCE (%)	20.7	16.4	17.1	19.6	22.6

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY23	FY24	FY25E	FY26E	FY27E
P/E (x)	121.6	94.4	72.4	55.7	41.6
P/CE(x)	77.2	59.1	45.4	34.8	26.6
P/B (x)	11.6	8.7	7.8	6.8	5.9
EV/Sales (x)	9.0	7.4	5.9	4.6	3.6
EV/EBITDA (x)	62.1	49.0	36.4	26.9	20.4
EV/EBIT(x)	89.1	72.6	53.0	38.6	28.6
EV/IC (x)	17.9	14.1	11.7	9.4	7.7
FCFF yield (%)	(0.8)	(0.1)	0.4	0.5	1.2
FCFE yield (%)	(0.8)	0.0	0.5	0.4	1.0
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0
DuPont-RoE split					
Net profit margin (%)	7.6	8.1	8.5	8.6	9.1
Total asset turnover (x)	1.7	1.3	1.3	1.5	1.7
Assets/Equity (x)	1.1	1.0	1.0	1.0	1.0
RoE (%)	14.0	10.7	11.3	13.0	15.1
DuPont-RoIC					
NOPLAT margin (%)	7.5	7.5	8.3	8.9	9.5
IC turnover (x)	2.5	2.2	2.2	2.3	2.3
RoIC (%)	18.7	16.4	18.1	20.2	22.2
Operating metrics					
Core NWC days	27.9	38.0	41.7	39.5	38.6
Total NWC days	144.4	153.9	147.9	145.9	142.9
Fixed asset turnover	8.6	7.7	7.7	7.9	8.3
Opex-to-revenue (%)	16.5	15.1	14.1	14.3	14.7


Source: Company, Emkay Research

## RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
23-Jul-24	2,897	3,200	Buy	Devanshu Bansal
07-Jul-24	2,813	3,200	Buy	Devanshu Bansal
26-Jun-24	2,776	3,200	Buy	Devanshu Bansal
14-May-24	2,411	2,950	Buy	Devanshu Bansal
07-Apr-24	2,542	2,950	Buy	Devanshu Bansal
11-Mar-24	2,752	2,850	Buy	Devanshu Bansal
15-Feb-24	2,399	2,850	Buy	Devanshu Bansal
10-Jan-24	2,295	2,300	Reduce	Devanshu Bansal
30-Nov-23	2,019	2,300	Add	Devanshu Bansal
16-Nov-23	2,005	2,300	Buy	Devanshu Bansal
08-Oct-23	1,718	2,000	Buy	Devanshu Bansal
07-Aug-23	1,544	1,770	Buy	Devanshu Bansal
10-Jul-23	1,515	1,540	Buy	Devanshu Bansal
23-Jun-23	1,299	1,540	Buy	Devanshu Bansal
15-May-23	1,275	1,540	Buy	Devanshu Bansal
09-Mar-23	989	1,400	Buy	Devanshu Bansal
04-Feb-23	1,003	1,400	Buy	Devanshu Bansal
09-Jan-23	1,017	1,400	Buy	Devanshu Bansal
25-Nov-22	918	1,400	Buy	Devanshu Bansal
08-Nov-22	1,017	1,400	Buy	Devanshu Bansal
18-Sep-22	988	1,400	Buy	Devanshu Bansal

Source: Company, Emkay Research

## RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research



**GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com).

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.



**RESTRICTIONS ON DISTRIBUTION**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons<sup>1</sup> may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of August 15, 2024
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report  
**Disclosure of previous investment recommendation produced:**
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of August 15, 2024
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the August 15, 2024
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

**Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.
<b>BUY</b>	>15% upside
<b>ADD</b>	5-15% upside
<b>REDUCE</b>	5% upside to 15% downside
<b>SELL</b>	<15% downside

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India  
Tel: +91 22 66121212 Fax: +91 22 66121299 Web: [www.emkayglobal.com](http://www.emkayglobal.com)

**OTHER DISCLAIMERS AND DISCLOSURES:****Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.